Statin Eligibility in Primary Prevention: From a Risk-Based Strategy to a Personalized Approach Based on the Predicted Benefit

      Guidelines have recommended statin initiation based on the absolute cardiovascular risk. We tested the hypothesis that a strategy based on the predicted cardiovascular benefit, compared with the risk-based approach, modifies statin eligibility and the estimated benefit in a population in primary cardiovascular prevention. The study included 16,008 subjects (48 ± 6 years, 73% men) with low-density lipoprotein cholesterol levels of 70 to <190 mg/dl, not on lipid-lowering drugs, who underwent a routine health screening in a single center. For the risk-based strategy, criterion for statin eligibility was defined as a 10-year atherosclerotic cardiovascular disease (ASCVD) risk of ≥7.5%. In the benefit-based strategy, subjects were considered for statin according to the predicted absolute cardiovascular risk reduction, so that the number of statin candidates would be the same as in the risk-based strategy. The benefit-based strategy would replace 11% of statin candidates allocated in the risk-based approach with younger, lower risk subjects with higher low-density lipoprotein cholesterol. Using the benefit-based strategy, 13% of subjects with 5.0% to < 7.5% ASCVD risk would shift from a statin-ineligible to a statin-eligible status, whereas 24% of those with 7.5% to <10.0% ASCVD risk would become statin ineligible. These effects would transfer the benefit from higher to lower risk subjects. In the entire population, no clinically meaningful change in the benefit would be expected. In conclusion, switching from a risk-based strategy to a benefit-based approach, while keeping the same rate of statin use in the population, is expected to promote substantial changes in statin eligibility in subjects at intermediate cardiovascular risk, modifying the subpopulation to be benefited by the treatment.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Stone N.J.
        • Robinson J.G.
        • Lichtenstein A.H.
        • Bairey Merz C.N.
        • Blum C.B.
        • Eckel R.H.
        • Goldberg A.C.
        • Gordon D.
        • Levy D.
        • Lloyd-Jones D.M.
        • McBride P.
        • Schwartz J.S.
        • Shero S.T.
        • Smith S.C.
        • Watson K.
        • Wilson P.W.F.
        2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 129: 2889-2934
        • Cholesterol Treatment Trialists' (CTT) Collaboration
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681
        • Collins R.
        • Reith C.
        • Emberson J.
        • Armitage J.
        • Baigent C.
        • Blackwell L.
        • Blumenthal R.
        • Danesh J.
        • Smith G.D.
        • DeMets D.
        • Evans S.
        • Law M.
        • MacMahon S.
        • Martin S.
        • Neal B.
        • Poulter N.
        • Preiss D.
        • Ridker P.
        • Roberts I.
        • Rodgers A.
        • Sandercock P.
        • Schulz K.
        • Sever P.
        • Simes J.
        • Smeeth L.
        • Wald N.
        • Yusuf S.
        • Peto R.
        Interpretation of the evidence for the efficacy and safety of statin therapy.
        Lancet. 2016; 388: 2532-2561
        • Soran H.
        • Schofield J.D.
        • Durrington P.N.
        Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment.
        Eur Heart J. 2015; 36: 2975-2983
        • Thanassoulis G.
        • Williams K.
        • Altobelli K.K.
        • Pencina M.J.
        • Cannon C.P.
        • Sniderman A.D.
        Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease.
        Circulation. 2016; 133: 1574-1581
        • Durrington P.N.
        • Soran H.
        Cholesterol levels should play a more important role in identifying statin recipients.
        Circulation. 2017; 135: 627-629
        • Thanassoulis G.
        • Pencina M.J.
        • Sniderman A.D.
        The benefit model for prevention of cardiovascular disease: an opportunity to harmonize guidelines.
        JAMA Cardiol. 2017; 2: 1175-1176
        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Goff D.C.
        • Lloyd-Jones D.M.
        • Bennett G.
        • Coady S.
        • D'Agostino R.B.
        • Gibbons R.
        • Greenland P.
        • Lackland D.T.
        • Levy D.
        • O'Donnell C.J.
        • Robinson J.G.
        • Schwartz J.S.
        • Shero S.T.
        • Smith S.C.
        • Sorlie P.
        • Stone N.J.
        • Wilson P.W.F.
        2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2935-2959
        • Rabar S.
        • Harker M.
        • O'Flynn N.
        • Wierzbicki A.S.
        Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance.
        BMJ. 2014; 349: g4356
        • Pletcher M.J.
        • Pignone M.
        • Jarmul J.A.
        • Moran A.E.
        • Vittinghoff E.
        • Newman T.
        Population impact & efficiency of benefit–targeted versus risk–targeted statin prescribing for primary prevention of cardiovascular disease.
        J Am Heart Assoc. 2017; 6: e004316
        • Cook N.R.
        • Ridker P.M.
        Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study.
        JAMA Intern Med. 2014; 174: 1964-1971
        • DeFilippis A.P.
        • Young R.
        • Carrubba C.J.
        • McEvoy J.W.
        • Budoff M.J.
        • Blumenthal R.S.
        • Kronmal R.A.
        • McClelland R.L.
        • Nasir K.
        • Blaha M.J.
        An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort.
        Ann Intern Med. 2015; 162: 266-275
        • Cholesterol Treatment Trialists' (CTT) Collaborators
        The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
        Lancet. 2012; 380: 581-590